Description:

A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B0F2A23-99E0-5C6F-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B0F2A23-99E0-5C6F-E044-0003BA3F9857

Keywords:
Versions (4) ▾
  1. 8/26/12
  2. 1/9/15
  3. 7/3/15
  4. 8/4/15
Uploaded on:

August 4, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Registration Breast Cancer NSABP B-40 NCT00408408

Submit every 6 months from date of randomization for the first 5 years; yearly thereafter, and when a protocol event occurs. Fax Form F to 412-622-2111

NSABP REGISTRATION FORM
Race (more than one may be marked)
Method of Payment (mark primary method only)
Ethnicity
Country of Residence (if not USA)
cm
kg
How Did The Patient Answer The Following Questions On The Consent Form
I agree to have blood samples collected three times during this study (These samples will be sent to the NSABP.)
My study doctor (or somone he or she shooses) may contact me in the future to ask me to take part in more research. (My study doctor or someone he or she chooses may contact me in the future to ask me to take part in more research.)
Stratification Factors
Lymph Node Involvement
Receptor Status
years
Certification of Eligibility
In the opinion of the investigator, is the patient eligible?
Has the patient authorized the release of Protected Health Information to the NSABP?
Diagnostic Core Needle Biopsy
Biopsy Specimens For B-40 Correlative Studies
Target Lesions
Target Lesion Site
cm

Similar models